| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Scribe Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $120.71M | Series B | 3/31/2021 | $100M | $351.77M | $35.83 | Avoro Ventures, Avoro Capital Advisors, OrbiMed, Andreessen Horowitz, Perceptive Advisors, T. Rowe Price, Wellington Management, RA Capital Management, Menlo Venture | ||||
 | Apnimed | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $249.52M | Series D-1 | 3/11/2026 | $25M | $491.51M | $13.03 | Undisclosed Investors | ||||
 | VeraDermics | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $263.24M | Series C | 10/16/2025 | $151M | $306.13M | $1.27 | SR One, Viking Global Investors, Marshall Wace, Invus, Abrdn, Columbia Threadneedle Investments, Infinitium, LifeSci Venture Partners, Longitude Capital, Suvretta Capital Management, Surveyor Capital | ||||
 | Alto Neuroscience | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $253.17M | Series C | 11/21/2023 | $50.31M | $235.65M | $4.71 | InVivium Capital, Franklin Templeton, Point72, Eli Lilly and Company, Alexandria Venture Investments, Alpha Wave Ventures, Lightswitch Capital, Alkeon Capital, WhatIf Ventures, Windham Venture Partners | ||||
 | Carlsmed | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $108.89M | Series C | 2/6/2025 | $64.72M | $245.25M | $10.74 | B Capital, U.S. Venture Partners | ||||
 | BioAge | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.42B | Series D | 2/13/2024 | $170M | $440.23M | $3.42 | Sofinnova Investments, Longitude Capital, RA Capital, Cormorant Asset Management, RTW Investments, SV Health Investors, OrbiMed Advisors, Sands Capital, Pivotal bioVenture Partners, Osage University Partners, Lilly Ventures, Amgen Ventures, Andreessen Horowitz | ||||
 | Spyglass Pharma | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $200.88M | Series D | 6/2/2025 | $77.33M | $363.51M | $13.33 | Sands Capital, Gilde Healthcare, New Enterprise Associates, RA Capital Management, Censana Capital, Samsara BioCapital, Vertex Ventures HC | ||||
 | BlossomHill Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $257.15M | Series B | 2/29/2024 | $184.15M | $400.87M | $17.63 | Colt Ventures, Cormorant Asset Management, OrbiMed, Vivo Capital, Hercules BioVentures Partners, Plaisance Capital Management, H&D Asset Management, Brahma Capital, Primer Ventures | ||||
 | Septerna | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $225M | Series B | 7/11/2023 | $150M | $313.42M | $1.23 | RA Capital Management, Third Rock Ventures, Samsara BioCapital, Invus, Catalio Capital Management, BVF Partners, Casdin Capital, Logos Capital, Deep Track Capital, Goldman Sachs Asset Management, Vertex Ventures HC, Mirae Asset Financial Group, Direhaus Capital Management, Woodline Partners LP, Soleus Capital | ||||
 | Aardvark Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $129.13M | Series C | 5/9/2024 | $85M | $267.58M | $1.77 | Decheng Capital, Cormorant Asset Management, Surveyor Capital, SymBiosis, Tetragon Financial Group, Walleye Capital, Laurion Capital Management, LG Technology Ventures, Cantor Ventures, Silver Arc Private Capital, Prader-Willi Syndrome Association, Vickers Venture Partners, Foundation for Prader-Willi Research | ||||
 | Alamar Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $248.57M | Series C | 2/26/2024 | $128.27M | $453.99M | $7.20 | Sands Capital, Sherpa Healthcare Partners, Pura Vida Investments | ||||
 | Evommune | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $268.46M | Series C | 10/31/2024 | $115.5M | $346.35M | $1.59 | RA Capital Management, Sectoral Asset Management, B Capital, Marshall Wace, Avego Bioscience Capital, Longwood Fund, RTW Investments, ADAR1 Capital Management, NEXTBio Capital, Beiersdorf Venture Capital, FemHealth Ventures, Allostery Investments LP, Pivotal bioVenture Partners, EQT Life Sciences, Andera Partners, Amplitude Ventures, SymBiosis, Verition Fund Management | ||||
 | MBX Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $216.64M | Series C | 8/5/2024 | $63.5M | $316.71M | $1.03 | Deep Track Capital, Driehaus Capital Management, T. Rowe Price Associates, Frazier Life Sciences, OrbiMed, Wellington Management | ||||
 | Rapport Therapeutics | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $250.18M | Series B | 8/7/2023 | $150M | $409.19M | $1.68 | Cormorant Asset Management, Fidelity Management & Research Company, Goldman Sachs Asset Management, Logos Capital, Perceptive Advisors, Sofinnova Investments, Surveyor Capital, Third Rock Ventures, ARCH Venture Partners, Johnson & Johnson Innovation | ||||
 | Contineum Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $133.61M | Series C | 2/11/2021 | $80.4M | $244.63M | $2.68 | Perceptive Advisors, Franklin Templeton, Casdin Capital, Samsara BioCapital, Suvretta Capital, Red Tree Venture Capital, Versant Ventures, Sectoral Asset Management, Cleva Pharma | ||||
 | Arcellx | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $235.48M | Series C | 4/13/2021 | $120M | $377.76M | $2.10 | Samsara BioCapital, CAM Capital, Adage, Asymmetry, CaaS Capital, Cambrian Bio, Sixty Degree, Soleus Capital, Surveyor Capital, Suvretta, Terra Magnum Capital Partners, New Enterprise Associates, Novo Holdings, SR One, Takeda Ventures, LG Tech, Clough Capital | ||||
 | Boundless Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $756.15M | Series C | 5/16/2023 | $100M | $273.76M | $0.70 | Bayer, RA Capital Management, Sectoral Asset Management, Piper Heartland, Healthcare Capital | ||||
 | Ceribell | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $153.6M | Series C-1 | 9/22/2022 | $100.39M | $328.64M | $11.49 | Longitude Capital, The Rise Fund, RA Capital Management, Redmile Group, Red Tree Venture Capital, Ally Bridge Group | ||||
 | ArriVent Biopharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $260M | Series B | 12/16/2022 | $110M | $375.08M | $1.05 | Undisclosed Investors | ||||
 | CAMP4 | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $113.77M | Series B | 7/20/2022 | $100.54M | $297.52M | $1.47 | Patient Square Capital, Gaingels, 5AM Ventures, Polaris Partners, Northpond Ventures, Andreessen Horowitz, The Kraft Group | ||||
 | Mineralys | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $159.18M | Series B | 6/8/2022 | $118M | $267.43M | $0.86 | RA Capital Management, Andera Partners, RTW Investments, Rock Springs Capital, SR One Capital Management, Sectoral Asset Management, Ysis Capital, HealthCor Management, Boulder Ventures, Catalys Pacific, Samsara BioCapital, HBM Healthcare Investments, Adams Street Partners | ||||
 | Attovia | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $255.85M | Series C | 4/15/2025 | $90M | $368.16M | $12.77 | Deep Track Capital, Vida Ventures, Sanofi Ventures, Mirae Asset Capital Life Science, Frazier Life Sciences, venBio, Goldman Sachs, Nextech Ventures, Cormorant Asset Management, EcoR1 Capital, Marshall Wace, Illumina Ventures | ||||
 | Aura Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $225.08M | Series E | 3/22/2021 | $80.48M | $283.03M | $0.78 | Matrix Capital Management, Surveyor Capital, Rock Springs Capital, Adage Capital Management LP, Velosity Capital, Medicxi, Advent Life Sciences, Lundbeckfonden Ventures, Arix Bioscience, Chiesi Ventures, Ysios Capital, Columbus Venture Partners | ||||
 | Bicara Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $710.05M | Series C | 12/12/2023 | $165M | $495.55M | $1.38 | Braidwell LP, TPG, The Rise Fund, Deerfield Management, Fairmount, Aisling Capital, Red Tree Venture Capital, RA Capital Management, F-Prime Capital, Eight Roads Ventures, Invus Piper Heartland Healthcare Capital, Premji Invest, Omega Funds, Bioqube Ventures, Acorn Bioventures, Janus Henderson Investors | ||||